Laszlo J, Goldstein D, Vugrin D, Hood L, Tso C Y
J Biol Response Mod. 1986 Aug;5(4):294-9.
A pilot study was undertaken to test whether alpha interferon (alpha-IFN) maintenance could continue to stabilize cancer measurements after induction therapy. Twenty-one patients who achieved stable disease at the end of their induction treatment were randomized to receive weekly maintenance with human lymphoblastoid interferon (HLBI) (3 MU/m2, i.m.) or to be followed and not given interferon. There were 12 patients in the maintenance groups and 9 in the control observation group. There was no time difference in disease progression between the two arms. This article considers the relevance of the stable disease category in trials of interferon.
开展了一项初步研究，以测试α干扰素（α-IFN）维持治疗能否在诱导治疗后继续稳定癌症测量值。21名在诱导治疗结束时病情稳定的患者被随机分组，分别接受人淋巴母细胞干扰素（HLBI）每周一次的维持治疗（3 MU/m²，肌肉注射）或接受随访且不给予干扰素。维持治疗组有12名患者，对照观察组有9名患者。两组在疾病进展方面没有时间差异。本文探讨了疾病稳定类别在干扰素试验中的相关性。
